公开(公告)号：US20200277252A1

公开(公告)日：2020-09-03

申请号：US16753035

申请日：2018-10-04

申请人： Meredeth Ann McGowan ,  Abdelghani Achab ,  Xavier Fradera ,  Yongxin Han ,  Derun Li ,  Jongwon Lim ,  Kun Liu ,  Nunzio Sciammetta ,  Catherine M. White ,  Wensheng Yu ,  Hongjun Zhang ,  Hua Zhou ,  MERCK SHARP & DOHME CORP.

发明人： Meredeth Ann McGowan ,  Abdelghani Achab ,  Xavier Fradera ,  Yongxin Han ,  Derun Li ,  Jongwon Lim ,  Kun Liu ,  Nunzio Sciammetta ,  Catherine M. White ,  Wensheng Yu ,  Hongjun Zhang ,  Hua Zhou

IPC分类号： C07C237/42 ,  C07D241/24 ,  C07D213/82 ,  C07D233/90 ,  C07D263/34 ,  C07D231/14 ,  C07D277/56 ,  C07D239/28 ,  C07D213/75 ,  C07D309/14 ,  C07D237/20 ,  C07D307/14 ,  C07D205/04 ,  C07D285/06 ,  C07D487/04

摘要： Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US11319283B2

公开(公告)日：2022-05-03

申请号：US16753035

申请日：2018-10-04

申请人： MERCK SHARP & DOHME CORP. ,  Meredeth Ann McGowan ,  Abdelghani Achab ,  Xavier Fradera ,  Yongxin Han ,  Derun Li ,  Jongwon Lim ,  Kun Liu ,  Nunzio Sciammetta ,  Catherine M. White ,  Wensheng Yu ,  Hongjun Zhang ,  Hua Zhou

发明人： Meredeth Ann McGowan ,  Abdelghani Achab ,  Xavier Fradera ,  Yongxin Han ,  Derun Li ,  Jongwon Lim ,  Kun Liu ,  Nunzio Sciammetta ,  Catherine M. White ,  Wensheng Yu ,  Hongjun Zhang ,  Hua Zhou

IPC分类号： C07D205/04 ,  C07C237/42 ,  C07D213/75 ,  C07D213/82 ,  C07D231/14 ,  C07D233/90 ,  C07D237/20 ,  C07D239/28 ,  C07D241/24 ,  C07D263/34 ,  C07D277/56 ,  C07D285/06 ,  C07D307/14 ,  C07D309/14 ,  C07D487/04

摘要： Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US11319295B2

公开(公告)日：2022-05-03

申请号：US16753043

申请日：2018-10-04

申请人： MERCK SHARP & DOHME CORP. ,  Catherine M. White ,  Meredeth Ann McGowan ,  Yongxin Han ,  Nunzio Sciammetta

发明人： Catherine M. White ,  Meredeth Ann McGowan ,  Yongxin Han ,  Nunzio Sciammetta

IPC分类号： C07D305/08 ,  A61P37/00 ,  A61P25/28 ,  A61P31/12 ,  A61P25/24 ,  A61P27/12 ,  A61P35/00 ,  C07D307/22 ,  C07D307/24 ,  C07D405/04 ,  A61K45/06

摘要： Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US20200239423A1

公开(公告)日：2020-07-30

申请号：US16753043

申请日：2018-10-04

申请人： Catherine M. WHITE ,  Meredeth Ann MCGOWAN ,  Yongxin HAN ,  Nunzio SCIAMMETTA ,  MERCK SHARP & DOHME CORP.

发明人： Catherine M. White ,  Meredeth Ann McGowan ,  Yongxin Han ,  Nunzio Sciammetta

IPC分类号： C07D305/08 ,  C07D307/24 ,  C07D307/22 ,  C07D405/04 ,  A61P35/00 ,  A61P31/12 ,  A61P25/24 ,  A61P25/28 ,  A61P27/12 ,  A61P37/00

摘要： Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US10745364B2

公开(公告)日：2020-08-18

申请号：US16270882

申请日：2019-02-08

申请人： Merck Sharp & Dohme Corp. ,  Lycera Corporation

发明人： Thomas D. Aicher ,  Chad A. VanHuis ,  William D. Thomas ,  John K. MacLean ,  Brian M. Andresen ,  Kenneth J. Barr ,  Corey E. Bienstock ,  Neville J. Anthony ,  Matthew Daniels ,  Kun Liu ,  Yuan Liu ,  Catherine M. White ,  Blair T. Lapointe ,  Nunzio Sciammetta ,  Vladimir Simov

IPC分类号： C07D265/36 ,  C07D413/14 ,  C07D215/58 ,  C07D401/06 ,  C07D401/12 ,  C07D413/04 ,  C07D471/04 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/538 ,  A61K45/06 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D487/04

摘要： The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.

公开(公告)号：US09809561B2

公开(公告)日：2017-11-07

申请号：US15103414

申请日：2014-12-19

申请人： Merck Sharp & Dohme Corp. ,  Lycera Corporation

发明人： Thomas D. Aicher ,  Chad A. VanHuis ,  William D. Thomas ,  John K. MacLean ,  Brian M. Andresen ,  Kenneth J. Barr ,  Corey E. Bienstock ,  Neville J. Anthony ,  Matthew Daniels ,  Kun Liu ,  Yuan Liu ,  Catherine M. White ,  Blair T. Lapointe ,  Nunzio Sciammetta ,  Vladimir Simov

IPC分类号： C07D265/36 ,  C07D413/14 ,  C07D215/58 ,  C07D401/06 ,  C07D401/12 ,  C07D413/04 ,  C07D471/04 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/538 ,  A61K45/06 ,  C07D413/06 ,  C07D413/12 ,  C07D417/06 ,  C07D487/04

CPC分类号： C07D265/36 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/538 ,  A61K45/06 ,  C07D215/58 ,  C07D401/06 ,  C07D401/12 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D471/04 ,  C07D487/04

摘要： The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.

公开(公告)号：US10377768B2

公开(公告)日：2019-08-13

申请号：US15587934

申请日：2017-05-05

申请人： Merck Sharp & Dohme Corp. ,  Lycera Corporation

发明人： Thomas D. Aicher ,  Kenneth J. Barr ,  Blair T. Lapointe ,  Vladimir Simov ,  Karin A. Stein ,  William D. Thomas ,  Peter L. Toogood ,  Chad A. Van Huis ,  Catherine M. White

IPC分类号： C07D498/04 ,  C07D413/06 ,  C07D471/04

摘要： The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.

公开(公告)号：US09657033B2

公开(公告)日：2017-05-23

申请号：US14398061

申请日：2013-05-07

申请人： Merck Sharp & Dohme Corp. ,  Lycera Corporation

发明人： Thomas D. Aicher ,  Kenneth J. Barr ,  Blair T. Lapointe ,  Vladimir Simov ,  Karin A. Stein ,  William D. Thomas ,  Peter L. Toogood ,  Chad A. Van Huis ,  Catherine M. White

IPC分类号： A61K31/397 ,  C07D498/04 ,  C07D413/06 ,  C07D471/04

CPC分类号： C07D498/04 ,  C07D413/06 ,  C07D471/04

摘要： The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.

公开(公告)号：US20200290996A1

公开(公告)日：2020-09-17

申请号：US16753050

申请日：2018-10-04

申请人： MERCK SHARP & DOHME CORP.

发明人： Catherine M. White ,  Abdelghani Achab ,  Indu T. Bharathan ,  Xavier Fradera ,  Yongxin Han ,  Derun Li ,  Jongwon Lim ,  Kun Liu ,  Meredeth Ann McGowan ,  Nunzio Sciammetta ,  Wensheng Yu ,  Hongjun Zhang ,  Hua Zhou

IPC分类号： C07D401/14 ,  C07D401/12 ,  C07D213/74 ,  C07D405/12 ,  C07D413/14 ,  C07D417/14

摘要： Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

公开(公告)号：US20180030005A1

公开(公告)日：2018-02-01

申请号：US15730997

申请日：2017-10-12

申请人： Merck Sharp & Dohme Corp. ,  Lycera Corporation

发明人： Thomas D. Aicher ,  Chad A. VanHuis ,  William D. Thomas ,  John K. MacLean ,  Brian M. Andresen ,  Kenneth J. Barr ,  Corey E. Bienstock ,  Neville J. Anthony ,  Matthew Daniels ,  Kun Liu ,  Yuan Liu ,  Catherine M. White ,  Blair T. Lapointe ,  Nunzio Sciammetta ,  Vladimir Simov

IPC分类号： C07D265/36 ,  A61K31/4375 ,  C07D417/06 ,  C07D413/14 ,  C07D413/12 ,  C07D413/06 ,  C07D413/04 ,  C07D401/12 ,  C07D401/06 ,  C07D215/58 ,  A61K45/06 ,  A61K31/538 ,  A61K31/4709 ,  A61K31/47 ,  C07D471/04 ,  C07D487/04

CPC分类号： C07D265/36 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/538 ,  A61K45/06 ,  C07D215/58 ,  C07D401/06 ,  C07D401/12 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D471/04 ,  C07D487/04 ,  Y02A50/409

摘要： The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.